IsomAb Closes Seed Financing for Development of Antibody Treatment for PAD

February 20, 2024—IsomAb Ltd, a United Kingdom–based biotechnology company, announced the closing of a £7.5 million (approximately US$9.4 million) seed financing round, which will enable the company to advance the preclinical development of its lead antibody, ISM-001, for the treatment of peripheral artery disease (PAD).

IsomAb is developing isoform-specific disease-modifying antibody treatments for serious and life-threatening diseases, with an initial focus on peripheral ischemia. The company was founded in 2022 as a spinout from the University of Nottingham in the United Kingdom.

Jackie Turnbull, CEO of IsomAb, commented in the company’s press release, “IsomAb’s lead program targeting VEGF-A₁₆₅b aims to treat PAD in the large proportion of patients with concomitant metabolic syndrome and type II diabetes. We are delighted to have attracted a group of high-quality investors to support the early development of our novel program toward Clinical Trial Application filing to enter the clinic.”

The seed financing round was led by Broadview Ventures, with further backing from existing investor SCVC and participation from the Midlands Engine Investment Fund (MEIF) Proof of Concept & Early Stage Fund, which is managed by Mercia Ventures. MEIF is supported financially by the European Union using funding from the European Regional Development Fund—as part of the European Structural and Investment Funds Growth Program 2014-2020—and the European Investment Bank.